The gut contains many resident bacteria with anaerobic bacteria, e.g. Bacteroides, bifidobacteria, being 100-1000 times more abundant than aerobic (facultative anaerobes), e.g. Escherichia, Enterobacter, Enterococcus. This gut microflora has major functions: -metabolic, e.g. fermentation of non-digestible dietary residues into short chain fatty acids as an energy source in the colon. -initiate vitamin K production. -control epithelial cell proliferation -involved in the development and maintenance of the immune system. -protect the gut mucosa from colonization by pathogenic bacteria. |
Although bacterial overgrowth may be responsible for the presenting symptoms, it must be remembered that many of the symptoms may be due to the underlying small bowel pathology. |
Treatment |
In the management of small intestinal bacterial overgrowth (SIBO), which of the following is true?
ReplyDeleteA. Antibiotic choice should be based on sensitivity analysis of jejunal aspirates.
B. Once the diagnosis is made continuous antibiotic therapy should be instituted unless a reversible underlying cause is found.
C. At least 2 antibiotics should be used in combination.
D. The efficacy of rifaximin in SIBO is based on highly efficient systemic absorption.
E. Antibiotic therapy in SIBO remains largely empirical.
correct answer E,
Antibiotic therapy in SIBO remains largely empiric and has not been the subject of many high quality randomized, controlled clinical trials. There is no evidence that antibiotic sensitivity testing is of value; some instances of SIBO may resolve with one course of antibiotics but most will require intermittent therapy. Even if more long-term therapy is required, courses of antibiotics should be separated by antibiotic-free holidays to minimize the likelihood of resistance. Rifaximin is minimally absorbed and owes its efficacy in SIBO to its intraluminal effects.
Which of the following has the best specificity for the diagnosis of small intestinal bacterial overgrowth (SIBO)?
ReplyDeleteA. Jejunal aspiration and culture
B. Jejunal aspiration and molecular analysis of the microbiota
C. Lactulose breath hydrogen test
D. Small bowel series
E. Glucose breath hydrogen test
correct answer A,
Though subject to criticism on a number of fronts, jejunal aspiration with culture and quantification of the number of colony forming units remains the most validated test for SIBO and while it may pose technical challenges and be subject to false negatives, it is highly specific for SIBO and more so than any of the breath tests. While molecular analysis offers much promise, it has yet to be validated in SIBO. Small bowel series may be useful in detecting a cause of SIBO but will not assist in the diagnosis of SIBO, per se.
Which of the following clinical features are associated with small intestinal bacterial overgrowth (SIBO)?
ReplyDeleteA. Folate deficiency
B. Protein-losing enteropathy
C. Vitamin K deficiency
D. Intestinal lymphoma
E. Enhanced iron absorption
correct answer B,
Anemia, in SIBO, is usually macrocytic because of malabsorption of vitamin B12 as a result of the binding and incorporation of this vitamin into the bacteria. Levels of both folate and vitamin K are, however, usually normal or elevated due to bacterial synthesis of these vitamins. Iron deficiency may occur as a consequence of bleeding from ulcers or erosions. In severe SIBO, mucosal injury my result in a protein-losing enteropathy. There is no direct association between SIBO and intestinal lymphoma.
SIBO classically causes a megaloblastic anemia due to vitamin B12 deficiency that is not reversible by use of intrinsic factor. Vitamin B12 deficiency is caused by bacterial consumption of the vitamin within the intestinal lumen before it can be absorbed across the mucosa. Anaerobic organisms mainly are responsible for the vitamin B12 deficiency. Unlike aerobic bacteria, anaerobes can use vitamin B12 in both its free form and as a complex with intrinsic factor. Anaerobic bacteria deprive the host of ingested vitamin B12 and exacerbate its deficiency by using ingested vitamin B12 to produce inactive cobamides that then compete with dietary vitamin B12 for ileal binding sites, thereby decreasing absorption of the vitamin.
ReplyDeleteI was diagnosed as HEPATITIS B carrier in 2013 with fibrosis of the
ReplyDeleteliver already present. I started on antiviral medications which
reduced the viral load initially. After a couple of years the virus
became resistant. I started on HEPATITIS B Herbal treatment from
ULTIMATE LIFE CLINIC (www.ultimatelifeclinic.com) in March, 2020. Their
treatment totally reversed the virus. I did another blood test after
the 6 months long treatment and tested negative to the virus. Amazing
treatment! This treatment is a breakthrough for all HBV carriers.